Scholarlink

Background <p>Children with complex congenital heart disease (CCHD) are at high risk for early neurodevelopmental delays across all domains. Neuromotor delay often emerges first and may impact broader development. Identifying early biomarkers of motor function could capture a critical window for intervention. We assessed the prognostic value of neuron-specific enolase (NSE) and S100B in predicting 4-month motor outcomes in newborns undergoing cardiac surgery with cardiopulmonary bypass (CPB).</p> Methods <p>Between December 2021 and October 2024, we conducted a prospective, single-centre study including term neonates with (CCHD) who required cardiac surgery within the first two months of life. NSE and S100B levels were measured at five perioperative time points. Blinded Alberta Infant Motor Scale (AIMS) assessment at four months evaluated motor outcomes.</p> Results <p>Of 35 newborns, 27 completed follow-up. Preoperative NSE levels were significantly higher in infants with AIMS scores below the 10th percentile (32.7 vs. 20.9 ng/mL, <i>p</i> = 0.044) and negatively correlated with AIMS percentiles (<i>ρ</i> = –0.617, <i>p</i> = 0.006. There was no significant association between motor outcomes, MRI findings or S100B levels.</p> Conclusions <p>Higher preoperative NSE levels predict poor early motor outcomes in CCHD and may be a marker for early risk stratification and intervention.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>Neuron-specific enolase (NSE) may serve as an early biomarker of neuromotor development in newborns with complex congenital heart disease (CCHD). Elevated preoperative NSE levels were associated with poorer motor outcomes at four months. NSE may serve as an additional biomarker within a multimodal risk stratification strategy, complementing clinical, imaging, and electrophysiological assessments to refine prognostic evaluation. These findings highlight the prognostic value of perioperative biomarkers for predicting early motor outcomes and support earlier identification of at-risk newborns, enabling targeted neurodevelopmental interventions. This work adds new evidence to limited literature on biological predictors of motor development after neonatal cardiac surgery.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early motor outcomes in infants with complex congenital heart disease: the predictive role of NSE and S100B

  • 期刊论文

  • 发表日期：

    2025年9月24日

查看全文
  • Narjess Boutalbi,
  • Samuel Dahan,
  • William Rozalen,
  • Thibault Beretti,
  • Laurene Fortis,
  • Lucie Delefosse,
  • Robin Cloarec,
  • Benoit Testud,
  • Virginie Fouilloux,
  • Célia Gran,
  • Giulia Danielou,
  • Florent Paoli,
  • Fedoua El-Louali,
  • Julie Blanc,
  • Camille Velly,
  • Guillaume Carles,
  • Chloe Wanert,
  • Sophie Quennelle,
  • Stéphane Lebel,
  • Solène Denantes,
  • Pierre Bourgoin,
  • Matthieu Laborier,
  • Sophie Arnaud,
  • Dominique Santelli,
  • Edouard Aries,
  • Chloé Allary,
  • Isabelle Grandvuillemin,
  • Clotilde Desrobert,
  • Johanna Calderon,
  • Farid Boubred,
  • Fabrice Michel,
  • Caroline Ovaert,
  • Mathieu Milh,
  • Marien Lenoir,
  • Béatrice Desnous

摘要

Background

Children with complex congenital heart disease (CCHD) are at high risk for early neurodevelopmental delays across all domains. Neuromotor delay often emerges first and may impact broader development. Identifying early biomarkers of motor function could capture a critical window for intervention. We assessed the prognostic value of neuron-specific enolase (NSE) and S100B in predicting 4-month motor outcomes in newborns undergoing cardiac surgery with cardiopulmonary bypass (CPB).

Methods

Between December 2021 and October 2024, we conducted a prospective, single-centre study including term neonates with (CCHD) who required cardiac surgery within the first two months of life. NSE and S100B levels were measured at five perioperative time points. Blinded Alberta Infant Motor Scale (AIMS) assessment at four months evaluated motor outcomes.

Results

Of 35 newborns, 27 completed follow-up. Preoperative NSE levels were significantly higher in infants with AIMS scores below the 10th percentile (32.7 vs. 20.9 ng/mL, p = 0.044) and negatively correlated with AIMS percentiles (ρ = –0.617, p = 0.006. There was no significant association between motor outcomes, MRI findings or S100B levels.

Conclusions

Higher preoperative NSE levels predict poor early motor outcomes in CCHD and may be a marker for early risk stratification and intervention.

Impact

Neuron-specific enolase (NSE) may serve as an early biomarker of neuromotor development in newborns with complex congenital heart disease (CCHD). Elevated preoperative NSE levels were associated with poorer motor outcomes at four months. NSE may serve as an additional biomarker within a multimodal risk stratification strategy, complementing clinical, imaging, and electrophysiological assessments to refine prognostic evaluation. These findings highlight the prognostic value of perioperative biomarkers for predicting early motor outcomes and support earlier identification of at-risk newborns, enabling targeted neurodevelopmental interventions. This work adds new evidence to limited literature on biological predictors of motor development after neonatal cardiac surgery.